ES2394952T3 - Derivados de axapéptido como inhibidores de la proteasa VIH - Google Patents

Derivados de axapéptido como inhibidores de la proteasa VIH Download PDF

Info

Publication number
ES2394952T3
ES2394952T3 ES11155667T ES11155667T ES2394952T3 ES 2394952 T3 ES2394952 T3 ES 2394952T3 ES 11155667 T ES11155667 T ES 11155667T ES 11155667 T ES11155667 T ES 11155667T ES 2394952 T3 ES2394952 T3 ES 2394952T3
Authority
ES
Spain
Prior art keywords
compound
pharmaceutically acceptable
composition
acceptable salt
efavirenz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11155667T
Other languages
English (en)
Spanish (es)
Inventor
Roger D Tung
Scott L Harbeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2394952T3 publication Critical patent/ES2394952T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
ES11155667T 2007-06-12 2008-06-12 Derivados de axapéptido como inhibidores de la proteasa VIH Active ES2394952T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US934201P 2007-06-12
US6762708P 2008-02-29 2008-02-29
US67627P 2008-02-29

Publications (1)

Publication Number Publication Date
ES2394952T3 true ES2394952T3 (es) 2013-02-07

Family

ID=39730784

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11155667T Active ES2394952T3 (es) 2007-06-12 2008-06-12 Derivados de axapéptido como inhibidores de la proteasa VIH
ES08252023T Active ES2356334T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa vih.
ES09075359T Active ES2395137T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa VIH

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES08252023T Active ES2356334T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa vih.
ES09075359T Active ES2395137T3 (es) 2007-06-12 2008-06-12 Derivados de azapéptidos como inhibidores de la proteasa VIH

Country Status (25)

Country Link
US (4) US20090036357A1 (enExample)
EP (3) EP2322509B1 (enExample)
JP (1) JP2010529196A (enExample)
KR (2) KR20120029480A (enExample)
CN (2) CN101711237B (enExample)
AR (1) AR066972A1 (enExample)
AT (2) ATE447554T1 (enExample)
AU (1) AU2008267048C1 (enExample)
BR (2) BRPI0813911A2 (enExample)
CA (1) CA2692028C (enExample)
CO (1) CO6241121A2 (enExample)
CY (1) CY1109766T1 (enExample)
DE (1) DE602008000255D1 (enExample)
DK (1) DK2003120T3 (enExample)
ES (3) ES2394952T3 (enExample)
HR (1) HRP20100065T1 (enExample)
MX (1) MX2009013565A (enExample)
PL (1) PL2003120T3 (enExample)
PT (1) PT2003120E (enExample)
RS (1) RS51226B (enExample)
RU (2) RU2448958C2 (enExample)
SI (1) SI2003120T1 (enExample)
TW (1) TW200908970A (enExample)
WO (1) WO2008156632A1 (enExample)
ZA (1) ZA200909079B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
WO2011080141A2 (en) 2009-12-21 2011-07-07 Tibotec Pharmaceuticals Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
EA024651B1 (ru) 2011-06-20 2016-10-31 Х. Лундбекк А/С Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
MX374931B (es) * 2015-12-02 2025-03-06 Merck Sharp & Dohme Llc Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
CN116033916A (zh) * 2020-04-16 2023-04-28 威斯康星州医药大学股份有限公司 用于治疗气道反流的hiv蛋白酶抑制剂气雾剂型制剂
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196607B (en) 1985-05-15 1988-12-28 Wellcome Found Process for producing dideoxy-nucleosides and pharmaceutics comprising such compounds
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
KR100187613B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테이제 억제 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
RS83503A (sr) 2001-05-03 2006-10-27 F. Hoffmann-La Roche Ag. Farmaceutska doza amorfnog nelfinavir mezilata
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ATE341332T1 (de) 2001-08-31 2006-10-15 Bristol Myers Squibb Co Verwendung von atazanavir in der hiv-therapie
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7553844B2 (en) 2003-02-21 2009-06-30 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US7718633B2 (en) * 2004-07-06 2010-05-18 Abbott Laboratories Prodrugs of HIV protease inhibitors
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
EP1934201A1 (en) 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
US20090036357A1 (en) 2009-02-05
SI2003120T1 (sl) 2010-03-31
US20120165288A1 (en) 2012-06-28
CN101711237A (zh) 2010-05-19
ATE447554T1 (de) 2009-11-15
KR20120029480A (ko) 2012-03-26
CA2692028A1 (en) 2008-12-24
US20110009355A1 (en) 2011-01-13
US20130041156A1 (en) 2013-02-14
HK1136576A1 (en) 2010-07-02
HRP20100065T1 (hr) 2010-03-31
EP2003120B1 (en) 2009-11-04
EP2003120B9 (en) 2010-06-02
PT2003120E (pt) 2010-02-11
ES2356334T3 (es) 2011-04-07
JP2010529196A (ja) 2010-08-26
RS51226B (sr) 2010-12-31
US8258309B2 (en) 2012-09-04
RU2012101881A (ru) 2013-07-27
HK1127345A1 (en) 2009-09-25
ZA200909079B (en) 2011-05-25
EP2322509B1 (en) 2012-08-22
CN102424668A (zh) 2012-04-25
CY1109766T1 (el) 2014-09-10
MX2009013565A (es) 2010-06-02
AU2008267048A1 (en) 2008-12-24
AU2008267048B2 (en) 2012-05-31
ES2395137T3 (es) 2013-02-08
AU2008267048C1 (en) 2013-01-17
CA2692028C (en) 2013-06-04
DE602008000255D1 (de) 2009-12-17
EP2322509A1 (en) 2011-05-18
CN101711237B (zh) 2013-08-07
EP2003120A1 (en) 2008-12-17
CO6241121A2 (es) 2011-01-20
ATE536343T1 (de) 2011-12-15
TW200908970A (en) 2009-03-01
US8158805B2 (en) 2012-04-17
RU2448958C2 (ru) 2012-04-27
PL2003120T3 (pl) 2010-04-30
BRPI0823520A2 (pt) 2013-12-17
BRPI0813911A2 (pt) 2012-02-22
EP2116532A1 (en) 2009-11-11
DK2003120T3 (da) 2010-03-15
KR101185899B1 (ko) 2012-09-27
WO2008156632A1 (en) 2008-12-24
EP2116532B1 (en) 2011-12-07
KR20100020033A (ko) 2010-02-19
AR066972A1 (es) 2009-09-23
RU2010100821A (ru) 2011-07-20

Similar Documents

Publication Publication Date Title
ES2394952T3 (es) Derivados de axapéptido como inhibidores de la proteasa VIH
ES2425183T3 (es) Derivados de oxazolidinonas sustituidas
US20090131363A1 (en) Deuterated darunavir
KR102132574B1 (ko) 트라이사이클릭 자이라제 억제제
WO2009148600A2 (en) Deuterated lysine-based compounds
ES2406479T3 (es) Derivado deuterado de 4-oxoquinolina para el tratamiento de la infección por VIH
US20130040914A1 (en) Prodrugs of an hiv reverse transcriptase inhibitor
EP2163553B1 (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof
WO2010132663A1 (en) Pegylated azapeptide derivatives as hiv protease inhibitors
HK1154862A (en) Azapeptide derivatives as hiv protease inhibitors
HK1127345B (en) Azapeptide derivatives as hiv protease inhibitors
AU2012216511A1 (en) Azapeptide derivatives
HK1136576B (en) Azapeptide derivatives as hiv protease inhibitors
WO2021257669A1 (en) Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same
HK1138580B (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof